查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1861444

性行为感染传染病检测市场按检测类型、最终用户、产品、技术、通路、疾病类型和检体类型划分－2025-2032年全球预测

STD Testing Market by Test Type, End User, Product, Technology, Distribution Channel, Disease Type, Sample Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，性行为感染检测市场规模将达到 160.3 亿美元，复合年增长率为 6.11%。

关键市场统计数据
基准年 2024 99.7亿美元
预计年份：2025年 105.8亿美元
预测年份 2032 160.3亿美元
复合年增长率 (%) 6.11%

权威深入剖析当前性行为感染检测格局，探讨创新、获取压力和不断演变的医疗服务模式如何影响这一格局。

随着技术进步、政策重点的转变以及医疗服务模式的演变，性传染性行为感染）检测领域正经历着快速且持续的变革。公共卫生计画、临床实验室和照护现场机构都在积极应对日益增长的对更快、更准确、更便捷诊断的需求，同时也面临着诸如社会污名、报销不均以及法规环境波动等持续存在的障碍。这些矛盾正在改变从集中式参考实验室到分散式照护现场机构等各种场所的检测方法的开发、检验和实施方式。

诊断技术开发人员和医疗系统正优先推进能够加快检测速度、扩大非侵入性采样范围以及实现多重病原体检测的创新，以简化临床决策流程。同时，数位化医疗整合和软体驱动的工作流程正在改善数据收集、报告和患者照护协调。因此，价值链上的各相关人员越来越关注互通性、品质保证以及在各种临床和社区环境中推广新型检测方法的可行性。

为了因应这种环境，领导者必须结合营运实际情况和监管限制来解读技术进步，同时确保公平取得服务。以下章节将深入探讨变革性变化、关税相关影响、市场细分洞察以及区域性考量，这些内容全面说明了当前性性行为感染检测的现状。

分子诊断、非侵入性采样、数位整合和分销模式的创新如何重塑性传染病检测服务和临床决策

该领域正经历多重变革，这些变革正在改变临床路径、供应链和病患体验。首先，分子诊断正透过简化的工作流程和强大的检体到结果平台，从专业实验室转移到更贴近患者的场所转移，从而利用核酸扩增技术实现更早、更可靠的检测。同时，等温扩增技术的进步和横向流动化验化学方法的改进，正在缩小快速检测和实验室检测之间的性能差距，为即时决策提供了更多选择。

其次，唾液和自采拭子等非侵入性检体类型的扩展降低了检测门槛，使得在传统临床环境之外进行广泛筛检成为可能。同时，支援远距结果交付、病患追踪和电子病例报告的软体和服务也促进了这一转变，从而建立了更一体化的医疗服务路径。第三，随着製造商和经销商采用全通路策略，分销和采购管道正在多元化发展。这些策略包括线上平台和分销网络直接向社区组织和家庭检测消费者销售产品。

最后，监管现代化和公共卫生优先事项正在推动适应性研究设计，并加快临床检验检测的核准流程。同时，对抗菌素抗药性日益增长的关注凸显了诊断指南治疗选择的必要性。总而言之，这些变化需要研发人员、实验室和卫生部门协调应对，以确保诊断效能、公平取得和检测专案的永续性。

评估2025年关税调整对诊断设备、套件以及整个检测生态系中最终用户的供应链和采购的累积影响。

2025年推出的贸易政策变化对支持性传染感染（性行为感染）诊断生态系统的采购、製造和分销管道产生了累积影响。影响进口设备、套件和组件的关税调整给供应链带来了压力，促使製造商和经销商重新评估其筹资策略和库存管理实践。因此，实验室、医院和参考实验室的采购团队必须权衡确保持续获得​​检测的必要性与营运现实（例如前置作业时间波动和供应商谈判）之间的关係。

为此，一些相关人员正在加快关键零件的在地采购，并在整个区域内寻找替代供应商，以降低贸易波动带来的风险。这些调整也影响产品系列，开发商正在考虑仪器设计和耗材规格对跨境物流和监管合规性的影响。对于需要快速补货的即时检测机构和线上销售管道就地检验，关税引发的波动凸显了与製造商和经销商签订强有力的分销协议以及透明定价的重要性。

此外，关税促使人们重新关注软体和服务作为价值差异化因素，诊断设备供应商纷纷投资服务包，以减少终端用户面临的供应中断风险。监管途径和报销谈判必须与筹资策略同步调整，以确保患者能够及时获得检测服务；相关人员也日益加强合作，制定合约保障措施和紧急时应对计画，以保护常规筛检和疫情应对能力。

综合細項分析揭示了测试类型、最终用户需求、产品形式、技术选择、通路、目标疾病和检体类型如何驱动策略重点。

详细的細項分析揭示了性传染性行为感染）检测领域内产品开发、分销和临床应用在多个维度上的差异。就检测类型而言，培养检测在抗菌药物敏感性试验和确诊流程中仍然至关重要，而琼脂培养和细胞培养则继续支持一些专业实验室功能。核酸增幅检查涵盖了基于PCR的平台和等温扩增方法。 PCR在灵敏检测方面仍发挥核心作用，而等温扩增方法则提供了更简单快速的检测方式，适用于分散式环境。快速检测包括横向流动化验和照护现场平台，这些平台优先考虑速度和易用性，而酵素免疫分析法）和侧向层析免疫检测检测则支持筛检和流行病学监测。

终端使用者有着不同的操作需求：诊断和参考实验室优先考虑的是通量、品管以及与实验室资讯系统的整合；医院和诊所强调的是工作流程效率和临床医生可解读性；而就地检验则重视易用性、快速结果报告和护理协调。产品类型也多种多样，从注重耐用性和与各种耗材相容性的仪器，到需要稳定供应链保障和货架稳定性的套件，再到能够增强数据管理、结果报告和远端患者互动的软体和服务，不一而足。酵素免疫分析法）、等温扩增、横向流动化验和聚合酶炼式反应（PCR）等技术，都需要在灵敏度、特异性、成本和操作复杂性之间进行权衡。

通路（直销、分销商、线上通路）决定了市场覆盖范围和用户支援模式，进而影响新检测方法在临床实践中的普及速度。不同病原体的疾病特异性各不相同。披衣菌感染和淋病检测通讯协定通常着重于核酸扩增方法，因为其诊断准确率高。疱疹检测则根据临床情况，结合直接检测和血清学检测。 HIV 检测整合了快速筛检和确诊性分子检测。梅毒诊断需要高灵敏度的血清学检测和反射性检测策略。检体类型影响使用者体验和接受度：血液和血清样本是血清学检测的标准样本，尿液和拭子检体是许多核酸检测的首选样本，而唾液检体因其便捷的筛检方式而日益普及。总而言之，这些细分因素共同影响着开发商和服务供应商的产品设计、监管策略和商业化路径。

区域流行病学、法规环境、生产能力和分销策略如何影响全球范围内的普及和获取差异

区域趋势在流行病学、法规结构、生产能力和医疗服务模式等方面呈现出重要的背景差异，这些差异影响着检测计画的实施。在美洲，公共卫生筛检计画与积极的私部门参与和成熟的实验室网络并存。就地检验和居家筛检日益普及，这得归功于数位化结果交付和广泛的分销管道。这些特点使得那些将强大的实验室能力与以用户为中心的设计以及与电子健康记录和病例报告系统的高度整合相结合的解决方案更具优势。

欧洲、中东和非洲地区（EMEA）的市场格局复杂多样，包括严格的监管路径、资源限制以及各国疾病流行率的波动。在此背景下，诊断试剂开发商必须权衡成本效益与严格的检验，并支援实验室基础设施的能力建设。与区域经销商和公共卫生机构建立伙伴关係对于扩大产品覆盖范围和确保品质保证至关重要，尤其是在以参考实验室和监测/疫情应对为重点的项目中。

亚太地区拥有众多主要製造地，诊断测试应用迅速普及，尤其註重可扩展生产、行动医疗整合和线上分销模式。大规模生产能力支持具有成本竞争力的套件製造，同时，对照护现场平台和远端医疗服务的投资不断增加，推动了对非侵入性采样和快速结果交付的需求。在所有地区，协调监管申报、加强本地检验研究以及优化分销策略对于确保产品部署与公共卫生目标和临床工作流程保持一致至关重要。

竞争洞察着重分析技术差异化、伙伴关係、监管策略和服务导向模式对市场定位和市场接受度的影响。

性行为感染感染诊断领域的竞争是由技术差异化、策略联盟以及超越核心检测能力的增值服务共同驱动的。主要企业正致力于提升分析灵敏度和特异性，同时透过简化工作流程和整合数位化报告来优化使用者体验。这种组合支援在中心实验室和患者床边等多种环境中部署，为那些能够证明产品具有实际效用和完善品质系统的企业创造了机会。

随着越来越多的公司寻求加速市场准入并缩短临床应用时间，设备製造商、套件供应商和分销合作伙伴之间的策略联盟日益普遍。此外，将诊断设备与软体和服务（例如连接解决方案、培训和售后支援）结合的公司，透过解决医院、诊所和照护现场机构面临的应用障碍，正在获得竞争优势。围绕新型扩增化学和多重检测方法的智慧财产权仍然是区分企业的关键因素，在多个司法管辖区获得监管批准的能力也同样重要。

市场相关人员也在探索差异化的商业模式，包括基于订阅的设备和耗材使用方式、涵盖品管和培训的综合服务协议，以及针对公共卫生客户的、强调经济性和规模化的项目。这些方法反映出一种更广泛的趋势，即解决方案应将产品性能与实际实施支援相结合，以促进永续应用。

经营团队可采取的策略重点，包括加强供应链韧性、加简介护现场、整合数位化工作流程以及与监管机构和公共卫生合作伙伴合作。

产业领导者应采取能够增强韧性、加快普及速度并最大限度地提升不同医疗环境下临床应用效果的策略。优先考虑供应链多元化和关键零件的多通路采购，可降低贸易中断和关税风险；同时，投资本地製造和组装，可缩短前置作业时间并有助于合规。此外，加速利用等温扩增技术和改进的侧向流动化学方法开发就地检验和快速检测，可扩大其在社区和分散式医疗机构的应用范围，使患者能够即时获得检测结果并及时接受治疗和通知合作伙伴。

领导者还应加强数位化整合，将连接性、自动化报告和决策支援功能融入其检测平台和服务产品中。这种整合将改善监测，简化个案管理，并增强对医院和公共卫生合作伙伴的价值提案。在商业性，透过采用全通路分销策略，结合面向大型机构客户的直接销售、用于本地渗透的经销商应对力以及面向更广泛消费者的线上管道，可以优化市场覆盖面和响应速度。

最后，各机构应积极与监管机构和公共卫生利益相关人员合作，简化检验流程，参与合作研究以证明其在不同人群中的临床效用，并设计定价和准入方案，以减少高需求社区的就医障碍。技术创新，结合切实可行的部署策略和相关人员的协作，可以持续改善检测覆盖率和临床疗效。

对用于得出研究结果的方法的透明度（关于主要访谈、次要证据综合、細項分析和品质保证通讯协定的详细资讯）

本报告的研究采用了一种综合性的混合方法，以确保分析的严谨性、情境有效性和可重复性。主要研究包括对临床实验室主任、照护现场专案经理、采购负责人和监管专家进行结构化访谈，以了解营运限制、实施驱动因素和采购考量。此外，还与诊断设备开发商和分销合作伙伴进行了讨论，以了解他们的产品开发蓝图和分销策略。

二次研究包括对同行评审文献、监管指导文件、白皮书和已发布的技术规范进行系统性回顾，以检验性能特征和技术属性。采用资料三角验证法，将主要访谈结果与已记录的证据进行交叉比对，以确保定性和定量指标的一致性。按测试类型、最终用户群、产品类型、技术、分销管道、疾病目标和检体类型进行細項分析，从而为开发人员和采购人员提供可操作的见解。

品质保证通讯协定包括对访谈结果进行交叉检验、反覆的专家评审以及对假设和局限性的透明记录。整个过程均遵循访谈知情同意和资料处理的伦理标准。调查方法强调基于现有证据的分析，避免推测性预测，并着重于经验因素和对相关人员的实际意义。

这份简明扼要的摘要重点阐述了创新、营运韧性和跨部门合作将如何影响性传染病检测的提供和取得方式。

摘要，目前性行为感染检测领域呈现出技术进步与实施复杂性并存的局面。核酸扩增技术、照护现场平台和非侵入性采样技术的进步虽然拓展了诊断能力，但供应链韧性、监管差异和物流配送等实际操作问题仍然限制这些技术的应用。那些能够使产品设计与终端用户工作流程相契合、投资于数位连接并积极管理采购风险的相关人员，将更有能力把创新转化为更佳的临床疗效。

区域差异凸显了製定客製化策略的重要性，例如在亚太地区充分利用其製造优势和线上管道，在欧洲、中东和非洲与监管机构和公共卫生机构建立合作关係，以及在美洲整合照护现场和居家检测模式。考虑疾病的具体需求和检体类型将进一步缩小部署方案的选择范围，并指南多重检测、血清学平台或基于培养的确认检测哪种方式最为理想。最终，製造商、实验室、临床医生、支付方和公共卫生机构之间的跨部门合作对于扩大有效且公平的检测项目规模至关重要。

展望未来，对品质、互通性和相关人员参与的严格把控将决定哪些创新能够永续地融入临床实践。透过专注于务实的实施和稳健的商业策略，该领域可以扩大高品质检测的覆盖范围，并加强对性行为感染影响的个人和社区的持续护理。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 消费者对可当日出结果且具有更高隐私保护功能的家用多重检测套组的需求日益增长。
  • 拓展远端医疗平台，提供结合性传染病筛检的虚拟咨询服务
  • 整合人工智慧（AI）驱动的诊断技术，以提高性行为感染传染病检测工作流程的准确性和速度
  • 透过药局和诊所合作提供快速性行为感染传染病检测服务
  • 消费者越来越多地接受基于订阅的性健康服务，并定期进行性行为感染监测
  • 利用区块链技术保护病患资料并增强性行为感染传染病检测报告的隐私性
  • 针对服务不足社区的行动侦测车的出现，使得按需进行性行为感染筛检和治疗成为可能。
  • 监管部门核准将促进披衣菌感染、淋病和其他性行为感染传染病多重快速检测的广泛应用
  • 智慧型手机连接诊断设备的开发使得性行为感染传染病检测结果的即时传输和追踪成为可能。
  • 加强对性行为感染传染病检测中抗菌素抗药性监测的重视，以指南标靶治疗通讯协定

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章性行为感染传染病检测市场（依检测类型划分）

  • 培养试验
    • 琼脂培养基培养法
    • 细胞培养
  • 核酸增幅检查
    • 等温扩增
    • 基于PCR的
  • 快速检测
    • 横向流动化验
    • 照护现场平台
  • 血清学检测
    • 酵素免疫分析法
    • 横向流动化验

第九章性行为感染传染病检测市场（依最终用户划分）

  • 诊断实验室
  • 医院和诊所
  • 即时侦测设施
  • 参考实验室

第十章性行为感染传染病检测市场（依产品划分）

  • 装置
  • 套件
  • 软体和服务

第十一章 按技术分類的性行为感染传染病检测市场

  • 酵素免疫分析法
  • 等温扩增
  • 横向流动化验
  • 基于PCR的

第十二章性行为感染传染病检测市场（依通路划分）

  • 直销
  • 批发商
  • 线上管道

第十三章性行为感染传染病检测市场（依疾病类型划分）

  • 披衣菌感染
  • 淋病
  • 疱疹
  • HIV
  • 梅毒

第十四章 依检体类型分類的性行为感染传染病检测市场

  • 血
  • 唾液
  • 拭子
  • 尿

第十五章 各地区性行为感染传染病检测市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十六章性行为感染传染病检测市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十七章 各国性行为感染传染病检测市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十八章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Laboratory Corporation of America Holdings
    • Quest Diagnostics Incorporated
    • Hologic, Inc.
    • F. Hoffmann-La Roche AG
    • Abbott Laboratories
    • Danaher Corporation
    • Becton Dickinson and Company
    • Bio-Rad Laboratories, Inc.
    • OraSure Technologies, Inc.
    • Quidel Corporation
Product Code: MRR-69324464D0F2

The STD Testing Market is projected to grow by USD 16.03 billion at a CAGR of 6.11% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 9.97 billion
Estimated Year [2025] USD 10.58 billion
Forecast Year [2032] USD 16.03 billion
CAGR (%) 6.11%

An authoritative orientation to the current sexually transmitted disease testing environment shaped by innovation, access pressures, and evolving care delivery models

The landscape of sexually transmitted disease testing is undergoing rapid and sustained transformation as technological advances converge with shifting policy priorities and evolving patterns of care delivery. Public health programs, clinical laboratories, and point-of-care providers are responding to rising demand for faster, more accurate, and accessible diagnostics while confronting persistent barriers such as stigma, inconsistent reimbursement, and variable regulatory environments. These tensions are reshaping how tests are developed, validated, and delivered across multiple settings, from centralized reference laboratories to decentralized point-of-care locations.

Diagnostics developers and health systems are prioritizing innovations that reduce time to result, expand non-invasive sampling, and enable multiplexed detection of pathogens to streamline clinical decision-making. At the same time, digital health integration and software-enabled workflows are improving data capture, reporting, and patient linkage to care. As a result, stakeholders across the value chain are increasingly focused on interoperability, quality assurance, and the practicalities of scaling novel testing modalities in diverse clinical and community contexts.

To navigate this environment, leaders must interpret technical advances in the context of operational realities and regulatory constraints while preserving equitable access. The following sections unpack the transformative shifts, tariff-related impacts, segmentation insights, and region-specific considerations that collectively define the current moment for STD testing.

How innovations in molecular methods, non-invasive sampling, digital integration, and distribution models are reshaping STD testing delivery and clinical decision-making

The field has experienced several transformative shifts that are altering clinical pathways, supply chains, and patient experiences. First, molecular diagnostics have migrated from specialized laboratories to near-patient settings through simplified workflows and robust sample-to-answer platforms, enabling nucleic acid amplification technologies to drive earlier and more reliable detection. Concurrently, advances in isothermal amplification techniques and improvements in lateral flow assay chemistry have narrowed performance gaps between rapid tests and laboratory-based assays, expanding options for immediate decision-making at the point of care.

Second, the expansion of non-invasive sample types such as saliva and self-collected swabs is lowering barriers to testing and enabling broader screening initiatives outside traditional clinical settings. This shift is complemented by software and services that support remote result delivery, patient follow-up, and electronic case reporting, creating more integrated care pathways. Third, distribution and procurement channels have diversified as manufacturers and distributors adopt omnichannel strategies, including direct sales, distributor networks, and online platforms that reach community-based organizations and home-testing consumers.

Finally, regulatory modernization and public health priorities have encouraged adaptive study designs and accelerated pathways for clinically-validated assays, while emerging attention to antimicrobial resistance underscores the need for diagnostics that inform treatment selection. Together, these shifts demand coordinated responses from developers, laboratories, and health authorities to ensure diagnostic performance, equitable access, and sustainability of testing programs.

Evaluating the cumulative supply chain and procurement consequences of 2025 tariff shifts on diagnostics instruments, kits, and end-user resilience across the testing ecosystem

Recent trade policy changes introduced in 2025 have produced cumulative effects across procurement, manufacturing, and distribution channels that serve the sexually transmitted disease diagnostics ecosystem. Tariff adjustments impacting imported instruments, kits, and component parts have pressured supply chains, prompting manufacturers and distributors to reassess sourcing strategies and inventory management practices. As a consequence, procurement teams in diagnostic laboratories, hospitals, and reference centers have had to balance the imperative for uninterrupted testing access with the operational realities of lead-time variability and supplier negotiation.

In response, some stakeholders have accelerated localization efforts for critical components and explored alternative suppliers across regions to reduce exposure to trade-related volatility. These adjustments have implications for product portfolios, as developers consider how instrument designs and consumable formats influence cross-border logistics and regulatory compliance. For point-of-care testing sites and online channels that rely on rapid replenishment, the tariff-driven dynamics have highlighted the importance of resilient distribution agreements and transparent pricing arrangements with manufacturers and distributors.

Moreover, tariffs have catalyzed renewed emphasis on software and services as value differentiators, with diagnostics providers investing in service packages that mitigate supply disruptions for end users. Regulatory pathways and reimbursement conversations must adapt alongside procurement strategies to preserve patient access to timely testing, and stakeholders are increasingly collaborating on contractual safeguards and contingency plans that protect routine screening and outbreak response capabilities.

Integrated segmentation analysis explains how test type, end-user needs, product form factors, technology selection, distribution channels, disease targets, and sample types drive strategic priorities

A granular view of segmentation reveals how product development, distribution, and clinical adoption vary across multiple dimensions of the STD testing landscape. When considering test type, culture tests remain relevant for antimicrobial susceptibility and confirmatory workflows, with agar-based culture and cell culture continuing to support specialized laboratory functions. Nucleic acid amplification tests encompass both PCR-based platforms and isothermal amplification methods; PCR maintains a central role for high-sensitivity detection while isothermal approaches enable simplified, rapid formats suited to decentralized settings. Rapid tests include lateral flow assays and point-of-care platforms that prioritize speed and ease of use, whereas serology testing through enzyme immunoassays and lateral flow immunoassays supports screening and epidemiological surveillance.

End users exhibit distinct operational requirements: diagnostic laboratories and reference laboratories prioritize throughput, quality control, and integration into laboratory information systems, hospitals and clinics focus on workflow efficiency and clinician-facing interpretability, and point-of-care testing sites emphasize ease of use, rapid turnaround, and linkage to care. Product types span instruments, where durability and compatibility with diverse consumables matter, kits that demand consistent supply chain assurance and shelf stability, and software and services that enhance data management, result reporting, and remote patient engagement. Technologies such as enzyme immunoassay, isothermal amplification, lateral flow assay, and PCR each present trade-offs between sensitivity, specificity, cost, and operational complexity.

Distribution channels-direct sales, distributors, and online channels-shape market reach and user support models, influencing how quickly new assays penetrate clinical practice. Disease-specific dynamics vary by pathogen: chlamydia and gonorrhea testing protocols often emphasize nucleic acid amplification for high diagnostic accuracy, herpes relies on a combination of direct detection and serology depending on clinical context, HIV testing integrates both rapid screening and confirmatory molecular assays, and syphilis diagnostics require sensitive serology with reflex testing strategies. Sample types influence user experience and adoption, with blood and serum samples remaining standard for serology, urine and swab specimens favored for many nucleic acid assays, and saliva increasingly used for user-friendly screening initiatives. Collectively, these segmentation layers inform product design, regulatory strategy, and commercialization pathways for developers and service providers.

How regional epidemiology, regulatory ecosystems, manufacturing capability, and distribution strategies shape differential adoption and access across global regions

Regional dynamics introduce critical contextual differences in epidemiology, regulatory frameworks, manufacturing capacity, and care delivery models that shape testing program implementation. In the Americas, substantial private sector participation and established laboratory networks coexist with active public health screening programs; the region shows strong uptake of point-of-care testing and home-based screening, supported by digital result delivery and broad distribution channels. These dynamics favor solutions that combine robust laboratory performance with user-focused design and strong connectivity to electronic health records and case reporting systems.

Europe, Middle East & Africa presents a heterogenous landscape characterized by stringent regulatory pathways in some markets, resource constraints in others, and variable disease prevalence across countries. Here, diagnostics developers must balance cost-effectiveness with rigorous validation and support capacity building for laboratory infrastructure. Partnerships with regional distributors and public health agencies are pivotal to expanding access and ensuring quality assurance, particularly for reference laboratories and programs focused on surveillance and outbreak response.

Asia-Pacific encompasses major manufacturing hubs and rapidly expanding diagnostic adoption, with a strong emphasis on scalable production, mobile health integration, and online distribution models. High-volume manufacturing capacity supports cost-competitive kit production, while rising investments in point-of-care platforms and telehealth services drive demand for non-invasive sampling and rapid result delivery. Across all regions, harmonizing regulatory submissions, strengthening local validation studies, and tailoring distribution strategies are essential to align product deployment with public health goals and clinical workflows.

Competitive landscape insights highlighting how technological differentiation, partnerships, regulatory strategy, and service-oriented models influence market positioning and adoption

Competitive dynamics in the STD diagnostics space are shaped by a mix of technological differentiation, strategic partnerships, and service-based offerings that extend beyond core assay performance. Leading developers are investing in features that improve analytical sensitivity and specificity while optimizing user experience through simplified workflows and integrated digital reporting. This combination supports adoption in both centralized laboratories and near-patient environments, creating opportunities for companies that can demonstrate real-world utility and robust quality systems.

Strategic alliances between instrument manufacturers, kit suppliers, and distribution partners are increasingly common as companies seek to accelerate market access and reduce time-to-adoption in clinical settings. Additionally, firms that pair diagnostics with software and services-such as connectivity solutions, training, and after-sales support-gain competitive advantage by addressing implementation barriers faced by hospitals, clinics, and point-of-care providers. Intellectual property around novel amplification chemistries and multiplexing approaches remains a differentiator, as does the ability to secure regulatory clearances across multiple jurisdictions.

Market actors are also exploring differentiated commercial models, including subscription-based access to instruments and consumables, bundled service agreements that include quality control and training, and targeted programs for public health customers that emphasize affordability and scale. These approaches reflect a broader pivot toward solutions that integrate product performance with practical deployment support to drive sustainable uptake.

Actionable strategic priorities for executives to strengthen supply resilience, accelerate point-of-care uptake, integrate digital workflows, and collaborate with regulators and public health partners

Industry leaders should pursue strategies that enhance resilience, accelerate access, and maximize clinical impact across diverse care settings. Prioritizing supply chain diversification and dual-source procurement for critical components will reduce exposure to trade disruptions and tariffs while investments in localized manufacturing or regional assembly can shorten lead times and support regulatory alignment. Concurrently, accelerating development of point-of-care and rapid testing modalities that leverage isothermal amplification and improved lateral flow chemistries will expand reach into community and decentralized settings where immediate results facilitate timely treatment and partner notification.

Leaders should also strengthen digital integration by embedding connectivity, automated reporting, and decision-support capabilities into test platforms and service offerings. This integration improves surveillance, simplifies case management, and enhances the value proposition for hospitals and public health partners. Commercially, adopting omnichannel distribution strategies-combining direct sales for large institutional customers, distributor relationships for regional penetration, and online channels for broader consumer access-will optimize market reach and responsiveness.

Finally, organizations should engage proactively with regulators and public health stakeholders to streamline validation pathways, participate in collaborative studies that demonstrate clinical utility across diverse populations, and design pricing and access programs that reduce barriers for high-need communities. By coupling technological innovation with pragmatic deployment strategies and stakeholder engagement, firms can drive sustainable improvements in testing coverage and clinical outcomes.

Methodological transparency detailing primary interviews, secondary evidence synthesis, segmentation analysis, and quality assurance protocols used to derive research findings

The research underpinning this report employed a comprehensive mixed-methods approach designed to ensure analytical rigor, contextual relevance, and reproducibility. Primary research included structured interviews with clinical laboratory directors, point-of-care program managers, procurement officers, and regulatory specialists to capture operational constraints, adoption drivers, and procurement considerations. These interviews were supplemented by consultations with diagnostic developers and distribution partners to understand product development roadmaps and channel strategies.

Secondary research encompassed systematic review of peer-reviewed literature, regulatory guidance documents, white papers, and publicly available technical specifications to validate performance characteristics and technology attributes. Data triangulation methods were applied to reconcile insights from primary interviews with documented evidence, ensuring consistency across qualitative and quantitative indicators. Segmentation analysis was performed across test type, end-user category, product typology, technology, distribution channel, disease target, and sample type to derive actionable insights for developers and purchasers.

Quality assurance protocols included cross-validation of interview findings, iterative review cycles with subject-matter experts, and transparent documentation of assumptions and limitations. Ethical standards for interview consent and data handling were observed throughout. While the methodology emphasizes current, evidence-based analysis, the report avoids speculative forecasting and instead focuses on empirical drivers and pragmatic implications for stakeholders.

A concise synthesis emphasizing how innovation, operational resilience, and cross-sector collaboration determine the trajectory of STD testing implementation and access

In synthesis, the current STD testing landscape reflects a balance between technological progress and implementation complexity. Advances in nucleic acid amplification, point-of-care platforms, and non-invasive sampling are expanding diagnostic capabilities, yet operational realities such as supply chain resilience, regulatory variability, and distribution logistics continue to temper adoption pathways. Stakeholders who align product design with end-user workflows, invest in digital connectivity, and proactively manage procurement risks will be better positioned to translate innovation into improved clinical outcomes.

Regional differences underscore the importance of tailored strategies, whether that means leveraging manufacturing strengths and online channels in Asia-Pacific, navigating regulatory and public health partnerships in Europe, Middle East & Africa, or integrating point-of-care and home-testing models across the Americas. Disease-specific needs and sample type considerations further refine deployment choices, informing where multiplex assays, serology platforms, or culture-based confirmation remain most appropriate. Ultimately, cross-sector collaboration among manufacturers, laboratories, clinicians, payers, and public health authorities is essential to scale testing programs that are both effective and equitable.

Moving forward, disciplined attention to quality, interoperability, and stakeholder engagement will determine which innovations achieve sustainable integration into clinical practice. By focusing on pragmatic implementation and resilient commercial strategies, the sector can expand access to high-quality testing and strengthen the continuum of care for individuals and communities affected by sexually transmitted infections.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Growing demand for at home multiplex STD testing kits with same day results and increased privacy
  • 5.2. Expansion of telemedicine platforms offering virtual consultations alongside STD screening
  • 5.3. Integration of AI driven diagnostics to improve accuracy and speed of STD detection workflows
  • 5.4. Partnerships between pharmacies and health clinics to provide point of care rapid STD testing services
  • 5.5. Rising consumer adoption of subscription based sexual health services with regular STD monitoring
  • 5.6. Implementation of blockchain technology to secure patient data and enhance privacy in STD test reporting
  • 5.7. Emergence of mobile testing vans targeting underserved communities for on demand STD screening and treatment
  • 5.8. Regulatory approvals accelerating the availability of multiplex rapid tests for chlamydia gonorrhea and other STDs
  • 5.9. Development of smartphone integrated diagnostic devices enabling instant STD result transmission and tracking
  • 5.10. Increased focus on antimicrobial resistance surveillance in STD testing to guide targeted treatment protocols

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. STD Testing Market, by Test Type

  • 8.1. Culture Tests
    • 8.1.1. Agar Based Culture
    • 8.1.2. Cell Culture
  • 8.2. Nucleic Acid Amplification Tests
    • 8.2.1. Isothermal Amplification
    • 8.2.2. PCR Based
  • 8.3. Rapid Tests
    • 8.3.1. Lateral Flow Assays
    • 8.3.2. Point Of Care Platforms
  • 8.4. Serology Tests
    • 8.4.1. Enzyme Immunoassay
    • 8.4.2. Lateral Flow Assays

9. STD Testing Market, by End User

  • 9.1. Diagnostic Laboratories
  • 9.2. Hospitals And Clinics
  • 9.3. Point Of Care Testing Sites
  • 9.4. Reference Laboratories

10. STD Testing Market, by Product

  • 10.1. Instruments
  • 10.2. Kits
  • 10.3. Software And Services

11. STD Testing Market, by Technology

  • 11.1. Enzyme Immunoassay
  • 11.2. Isothermal Amplification
  • 11.3. Lateral Flow Assay
  • 11.4. PCR Based

12. STD Testing Market, by Distribution Channel

  • 12.1. Direct Sales
  • 12.2. Distributors
  • 12.3. Online Channels

13. STD Testing Market, by Disease Type

  • 13.1. Chlamydia
  • 13.2. Gonorrhea
  • 13.3. Herpes
  • 13.4. HIV
  • 13.5. Syphilis

14. STD Testing Market, by Sample Type

  • 14.1. Blood
  • 14.2. Saliva
  • 14.3. Swab
  • 14.4. Urine

15. STD Testing Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. STD Testing Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. STD Testing Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. Competitive Landscape

  • 18.1. Market Share Analysis, 2024
  • 18.2. FPNV Positioning Matrix, 2024
  • 18.3. Competitive Analysis
    • 18.3.1. Laboratory Corporation of America Holdings
    • 18.3.2. Quest Diagnostics Incorporated
    • 18.3.3. Hologic, Inc.
    • 18.3.4. F. Hoffmann-La Roche AG
    • 18.3.5. Abbott Laboratories
    • 18.3.6. Danaher Corporation
    • 18.3.7. Becton Dickinson and Company
    • 18.3.8. Bio-Rad Laboratories, Inc.
    • 18.3.9. OraSure Technologies, Inc.
    • 18.3.10. Quidel Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL STD TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL STD TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL STD TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL STD TESTING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL STD TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL STD TESTING MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL STD TESTING MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL STD TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL STD TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL STD TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL STD TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL STD TESTING MARKET SIZE, BY DISEASE TYPE, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL STD TESTING MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL STD TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 15. GLOBAL STD TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL STD TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AMERICAS STD TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. NORTH AMERICA STD TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. LATIN AMERICA STD TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. EUROPE STD TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. MIDDLE EAST STD TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. AFRICA STD TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC STD TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GLOBAL STD TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. ASEAN STD TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GCC STD TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. EUROPEAN UNION STD TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BRICS STD TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. G7 STD TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. NATO STD TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 32. GLOBAL STD TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 33. STD TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 34. STD TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. STD TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL STD TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL STD TESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL STD TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL STD TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL STD TESTING MARKET SIZE, BY CULTURE TESTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL STD TESTING MARKET SIZE, BY CULTURE TESTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL STD TESTING MARKET SIZE, BY CULTURE TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL STD TESTING MARKET SIZE, BY CULTURE TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL STD TESTING MARKET SIZE, BY CULTURE TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL STD TESTING MARKET SIZE, BY CULTURE TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL STD TESTING MARKET SIZE, BY CULTURE TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL STD TESTING MARKET SIZE, BY CULTURE TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL STD TESTING MARKET SIZE, BY AGAR BASED CULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL STD TESTING MARKET SIZE, BY AGAR BASED CULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL STD TESTING MARKET SIZE, BY AGAR BASED CULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL STD TESTING MARKET SIZE, BY AGAR BASED CULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL STD TESTING MARKET SIZE, BY AGAR BASED CULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL STD TESTING MARKET SIZE, BY AGAR BASED CULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL STD TESTING MARKET SIZE, BY CELL CULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL STD TESTING MARKET SIZE, BY CELL CULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL STD TESTING MARKET SIZE, BY CELL CULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL STD TESTING MARKET SIZE, BY CELL CULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL STD TESTING MARKET SIZE, BY CELL CULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL STD TESTING MARKET SIZE, BY CELL CULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL STD TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL STD TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL STD TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL STD TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL STD TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL STD TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL STD TESTING MARKET SIZE, BY PCR BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL STD TESTING MARKET SIZE, BY PCR BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL STD TESTING MARKET SIZE, BY PCR BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL STD TESTING MARKET SIZE, BY PCR BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL STD TESTING MARKET SIZE, BY PCR BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL STD TESTING MARKET SIZE, BY PCR BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL STD TESTING MARKET SIZE, BY RAPID TESTS, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL STD TESTING MARKET SIZE, BY RAPID TESTS, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL STD TESTING MARKET SIZE, BY RAPID TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL STD TESTING MARKET SIZE, BY RAPID TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL STD TESTING MARKET SIZE, BY RAPID TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL STD TESTING MARKET SIZE, BY RAPID TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL STD TESTING MARKET SIZE, BY RAPID TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL STD TESTING MARKET SIZE, BY RAPID TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL STD TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL STD TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL STD TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL STD TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL STD TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL STD TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL STD TESTING MARKET SIZE, BY POINT OF CARE PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL STD TESTING MARKET SIZE, BY POINT OF CARE PLATFORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL STD TESTING MARKET SIZE, BY POINT OF CARE PLATFORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL STD TESTING MARKET SIZE, BY POINT OF CARE PLATFORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL STD TESTING MARKET SIZE, BY POINT OF CARE PLATFORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL STD TESTING MARKET SIZE, BY POINT OF CARE PLATFORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL STD TESTING MARKET SIZE, BY SEROLOGY TESTS, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL STD TESTING MARKET SIZE, BY SEROLOGY TESTS, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL STD TESTING MARKET SIZE, BY SEROLOGY TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL STD TESTING MARKET SIZE, BY SEROLOGY TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL STD TESTING MARKET SIZE, BY SEROLOGY TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL STD TESTING MARKET SIZE, BY SEROLOGY TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL STD TESTING MARKET SIZE, BY SEROLOGY TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL STD TESTING MARKET SIZE, BY SEROLOGY TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL STD TESTING MARKET SIZE, BY ENZYME IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL STD TESTING MARKET SIZE, BY ENZYME IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL STD TESTING MARKET SIZE, BY ENZYME IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL STD TESTING MARKET SIZE, BY ENZYME IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL STD TESTING MARKET SIZE, BY ENZYME IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL STD TESTING MARKET SIZE, BY ENZYME IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL STD TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL STD TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL STD TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL STD TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL STD TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL STD TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL STD TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL STD TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL STD TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL STD TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL STD TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL STD TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL STD TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL STD TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL STD TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL STD TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL STD TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL STD TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL STD TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL STD TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL STD TESTING MARKET SIZE, BY POINT OF CARE TESTING SITES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL STD TESTING MARKET SIZE, BY POINT OF CARE TESTING SITES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL STD TESTING MARKET SIZE, BY POINT OF CARE TESTING SITES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL STD TESTING MARKET SIZE, BY POINT OF CARE TESTING SITES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL STD TESTING MARKET SIZE, BY POINT OF CARE TESTING SITES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL STD TESTING MARKET SIZE, BY POINT OF CARE TESTING SITES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL STD TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL STD TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL STD TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL STD TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL STD TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL STD TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL STD TESTING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL STD TESTING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL STD TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL STD TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL STD TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL STD TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL STD TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL STD TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL STD TESTING MARKET SIZE, BY KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL STD TESTING MARKET SIZE, BY KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL STD TESTING MARKET SIZE, BY KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL STD TESTING MARKET SIZE, BY KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL STD TESTING MARKET SIZE, BY KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL STD TESTING MARKET SIZE, BY KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL STD TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL STD TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL STD TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL STD TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL STD TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL STD TESTING MARKET SIZE, BY SOFTWARE AND SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL STD TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL STD TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL STD TESTING MARKET SIZE, BY ENZYME IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL STD TESTING MARKET SIZE, BY ENZYME IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL STD TESTING MARKET SIZE, BY ENZYME IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL STD TESTING MARKET SIZE, BY ENZYME IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL STD TESTING MARKET SIZE, BY ENZYME IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL STD TESTING MARKET SIZE, BY ENZYME IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL STD TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL STD TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL STD TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL STD TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL STD TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL STD TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL STD TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL STD TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL STD TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL STD TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL STD TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL STD TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL STD TESTING MARKET SIZE, BY PCR BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL STD TESTING MARKET SIZE, BY PCR BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL STD TESTING MARKET SIZE, BY PCR BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL STD TESTING MARKET SIZE, BY PCR BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL STD TESTING MARKET SIZE, BY PCR BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL STD TESTING MARKET SIZE, BY PCR BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL STD TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL STD TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL STD TESTING MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL STD TESTING MARKET SIZE, BY DIRECT SALES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL STD TESTING MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL STD TESTING MARKET SIZE, BY DIRECT SALES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL STD TESTING MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL STD TESTING MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL STD TESTING MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL STD TESTING MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL STD TESTING MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL STD TESTING MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL STD TESTING MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL STD TESTING MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL STD TESTING MARKET SIZE, BY ONLINE CHANNELS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL STD TESTING MARKET SIZE, BY ONLINE CHANNELS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL STD TESTING MARKET SIZE, BY ONLINE CHANNELS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL STD TESTING MARKET SIZE, BY ONLINE CHANNELS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL STD TESTING MARKET SIZE, BY ONLINE CHANNELS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL STD TESTING MARKET SIZE, BY ONLINE CHANNELS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL STD TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL STD TESTING MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL STD TESTING MARKET SIZE, BY CHLAMYDIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL STD TESTING MARKET SIZE, BY CHLAMYDIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL STD TESTING MARKET SIZE, BY CHLAMYDIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL STD TESTING MARKET SIZE, BY CHLAMYDIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL STD TESTING MARKET SIZE, BY CHLAMYDIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL STD TESTING MARKET SIZE, BY CHLAMYDIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL STD TESTING MARKET SIZE, BY GONORRHEA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL STD TESTING MARKET SIZE, BY GONORRHEA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL STD TESTING MARKET SIZE, BY GONORRHEA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL STD TESTING MARKET SIZE, BY GONORRHEA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL STD TESTING MARKET SIZE, BY GONORRHEA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL STD TESTING MARKET SIZE, BY GONORRHEA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL STD TESTING MARKET SIZE, BY HERPES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL STD TESTING MARKET SIZE, BY HERPES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL STD TESTING MARKET SIZE, BY HERPES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL STD TESTING MARKET SIZE, BY HERPES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL STD TESTING MARKET SIZE, BY HERPES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL STD TESTING MARKET SIZE, BY HERPES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL STD TESTING MARKET SIZE, BY HIV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL STD TESTING MARKET SIZE, BY HIV, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL STD TESTING MARKET SIZE, BY HIV, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL STD TESTING MARKET SIZE, BY HIV, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL STD TESTING MARKET SIZE, BY HIV, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL STD TESTING MARKET SIZE, BY HIV, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL STD TESTING MARKET SIZE, BY SYPHILIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL STD TESTING MARKET SIZE, BY SYPHILIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL STD TESTING MARKET SIZE, BY SYPHILIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL STD TESTING MARKET SIZE, BY SYPHILIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL STD TESTING MARKET SIZE, BY SYPHILIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL STD TESTING MARKET SIZE, BY SYPHILIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL STD TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL STD TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL STD TESTING MARKET SIZE, BY BLOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL STD TESTING MARKET SIZE, BY BLOOD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL STD TESTING MARKET SIZE, BY BLOOD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL STD TESTING MARKET SIZE, BY BLOOD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL STD TESTING MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL STD TESTING MARKET SIZE, BY BLOOD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL STD TESTING MARKET SIZE, BY SALIVA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL STD TESTING MARKET SIZE, BY SALIVA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL STD TESTING MARKET SIZE, BY SALIVA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL STD TESTING MARKET SIZE, BY SALIVA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL STD TESTING MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL STD TESTING MARKET SIZE, BY SALIVA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL STD TESTING MARKET SIZE, BY SWAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL STD TESTING MARKET SIZE, BY SWAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL STD TESTING MARKET SIZE, BY SWAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL STD TESTING MARKET SIZE, BY SWAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL STD TESTING MARKET SIZE, BY SWAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL STD TESTING MARKET SIZE, BY SWAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL STD TESTING MARKET SIZE, BY URINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL STD TESTING MARKET SIZE, BY URINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL STD TESTING MARKET SIZE, BY URINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL STD TESTING MARKET SIZE, BY URINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL STD TESTING MARKET SIZE, BY URINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL STD TESTING MARKET SIZE, BY URINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL STD TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL STD TESTING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS STD TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS STD TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS STD TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS STD TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS STD TESTING MARKET SIZE, BY CULTURE TESTS, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS STD TESTING MARKET SIZE, BY CULTURE TESTS, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS STD TESTING MARKET SIZE, BY RAPID TESTS, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS STD TESTING MARKET SIZE, BY RAPID TESTS, 2025-2032 (USD MILLION)
  • TABLE 249. AMERICAS STD TESTING MARKET SIZE, BY SEROLOGY TESTS, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS STD TESTING MARKET SIZE, BY SEROLOGY TESTS, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS STD TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS STD TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 253. AMERICAS STD TESTING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS STD TESTING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS STD TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS STD TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS STD TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS STD TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS STD TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS STD TESTING MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS STD TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS STD TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. NORTH AMERICA STD TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. NORTH AMERICA STD TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA STD TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. NORTH AMERICA STD TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA STD TESTING MARKET SIZE, BY CULTURE TESTS, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA STD TESTING MARKET SIZE, BY CULTURE TESTS, 2025-2032 (USD MILLION)
  • TABLE 269. NORTH AMERICA STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2024 (USD MILLION)
  • TABLE 270. NORTH AMERICA STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2025-2032 (USD MILLION)
  • TABLE 271. NORTH AMERICA STD TESTING MARKET SIZE, BY RAPID TESTS, 2018-2024 (USD MILLION)
  • TABLE 272. NORTH AMERICA STD TESTING MARKET SIZE, BY RAPID TESTS, 2025-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA STD TESTING MARKET SIZE, BY SEROLOGY TESTS, 2018-2024 (USD MILLION)
  • TABLE 274. NORTH AMERICA STD TESTING MARKET SIZE, BY SEROLOGY TESTS, 2025-2032 (USD MILLION)
  • TABLE 275. NORTH AMERICA STD TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 276. NORTH AMERICA STD TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 277. NORTH AMERICA STD TESTING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 278. NORTH AMERICA STD TESTING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 279. NORTH AMERICA STD TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 280. NORTH AMERICA STD TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 281. NORTH AMERICA STD TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 282. NORTH AMERICA STD TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 283. NORTH AMERICA STD TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. NORTH AMERICA STD TESTING MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. NORTH AMERICA STD TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. NORTH AMERICA STD TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 287. LATIN AMERICA STD TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. LATIN AMERICA STD TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. LATIN AMERICA STD TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. LATIN AMERICA STD TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. LATIN AMERICA STD TESTING MARKET SIZE, BY CULTURE TESTS, 2018-2024 (USD MILLION)
  • TABLE 292. LATIN AMERICA STD TESTING MARKET SIZE, BY CULTURE TESTS, 2025-2032 (USD MILLION)
  • TABLE 293. LATIN AMERICA STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2024 (USD MILLION)
  • TABLE 294. LATIN AMERICA STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2025-2032 (USD MILLION)
  • TABLE 295. LATIN AMERICA STD TESTING MARKET SIZE, BY RAPID TESTS, 2018-2024 (USD MILLION)
  • TABLE 296. LATIN AMERICA STD TESTING MARKET SIZE, BY RAPID TESTS, 2025-2032 (USD MILLION)
  • TABLE 297. LATIN AMERICA STD TESTING MARKET SIZE, BY SEROLOGY TESTS, 2018-2024 (USD MILLION)
  • TABLE 298. LATIN AMERICA STD TESTING MARKET SIZE, BY SEROLOGY TESTS, 2025-2032 (USD MILLION)
  • TABLE 299. LATIN AMERICA STD TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 300. LATIN AMERICA STD TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 301. LATIN AMERICA STD TESTING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 302. LATIN AMERICA STD TESTING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 303. LATIN AMERICA STD TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 304. LATIN AMERICA STD TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 305. LATIN AMERICA STD TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 306. LATIN AMERICA STD TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 307. LATIN AMERICA STD TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 308. LATIN AMERICA STD TESTING MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 309. LATIN AMERICA STD TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 310. LATIN AMERICA STD TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 312. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 313. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 314. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 315. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY CULTURE TESTS, 2018-2024 (USD MILLION)
  • TABLE 316. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY CULTURE TESTS, 2025-2032 (USD MILLION)
  • TABLE 317. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2024 (USD MILLION)
  • TABLE 318. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2025-2032 (USD MILLION)
  • TABLE 319. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY RAPID TESTS, 2018-2024 (USD MILLION)
  • TABLE 320. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY RAPID TESTS, 2025-2032 (USD MILLION)
  • TABLE 321. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY SEROLOGY TESTS, 2018-2024 (USD MILLION)
  • TABLE 322. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY SEROLOGY TESTS, 2025-2032 (USD MILLION)
  • TABLE 323. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 324. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 325. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 326. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 327. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 328. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 329. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 330. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 331. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 332. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 333. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 334. EUROPE, MIDDLE EAST & AFRICA STD TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 335. EUROPE STD TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 336. EUROPE STD TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 337. EUROPE STD TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 338. EUROPE STD TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 339. EUROPE STD TESTING MARKET SIZE, BY CULTURE TESTS, 2018-2024 (USD MILLION)
  • TABLE 340. EUROPE STD TESTING MARKET SIZE, BY CULTURE TESTS, 2025-2032 (USD MILLION)
  • TABLE 341. EUROPE STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2018-2024 (USD MILLION)
  • TABLE 342. EUROPE STD TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, 2025-2032 (USD MILLION)
  • TABLE 343. EUROPE STD TESTING MARKET SIZE, BY RAPID TESTS, 2018-2024 (USD MILLION)
  • TABLE 344. EUROPE STD TESTING MARKET SIZE, BY RAPID TESTS, 2025-2032 (USD MILLION)
  • TABLE 345. EUROPE STD TESTING MARKET SIZE, BY SEROLOGY TESTS, 2018-2024 (USD MILLION)
  • TABLE 346. EUROPE STD TESTING MARKET SIZE, BY SEROLOGY TESTS, 2025-2032 (USD MILLION)
  • TABLE 347. EUROPE STD TESTING MARKET SIZ